No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

4/1

Merck KGaA

Abbisko

Therapeutics

Pimicotinib

CSF-1R antagonist

Oncology

Tenosynovial giant cell

tumors (TGCTs)

Phase 3

605.5

2

4/2

Sanofi

Nurix Therapeutics

n/d

Targeted protein degrader

Immunology

Autoimmune diseases

n/d

480

3

4/3

Eli Lilly

Sangamo

Therapeutics

STAC-BBB

Capsid delivery platform

Neurology

CNS disease

n/d

1,400

4

4/7

GSK

ABL Bio

Grabody-B

Platform

Tech to bypass blood-brain barrier
(targeting IGF1R)

Neurology

Neurodegenerative

brain diseases

-

2,500

5

4/14

U.S.-based

ADC developer

Abion

ABN501

αCLDN3 mAb

Oncology

Solid tumor; SCLC

Preclinical

800

6

4/15

MSD

Cyprumed

n/d

Oral peptide delivery platform

-

-

-

493

7

4/15

Boehringer Ingelheim

Cue Biopharma

CUE-501

B-cell depletion compounds

Immunology

Autoimmune diseases

Preclinical

357

8

4/17

Eli Lilly

BigHat Biosciences

MillinerTM

AI - driven antibody drug

development platform

-

-

-

n/d

9

4/17

Sanofi

Earendil Labs

HXN-1002

HXN-1003

α4β7 x TL1A BsAbs

IL23 x TL1A BsAbs

Immunology

Immunology

Crohn’s disease

Ulcerative Colitis

Preclinical

Preclinical

1,800

10

4/23

Boehringer Ingelheim

Tessellate bio

ALT Program

PARP inhibitor

Oncology

ALT-positive tumor

n/d

570

11

4/23

Roche

(Genentech)

Repertoire

Immune

Medicines

Decode platform

Immune-modeling platform

Immunology

Autoimmune diseases

Preclinical

765

12

4/29

Eli Lilly

Creyon Bio AI

n/d

Platform to find oligonucleotide-

based medicines

-

-

-

1,013

13

4/30

Addex

Therapeutics

Sinntaxis AB

Dipraglurant-IR

mGlu5 negative allosteric

modulator

Neurology

Brain injury

Phase 3

n/d

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

4/2

Concentra Biosciences

Allakos

AK006

Siglec-6 agonist

Immunology

Chronic Urticaria, Inflammation

Phase 1

29.76

2

4/8

Onconetix

Ocuvex Therapeutics

Omlonti

PGE2 receptor EP2 subtype agonist

Ophthalmology

Glaucoma

Marketed

n/d

3

4/15

Norgine

Theravia

Siklos

DNA synthesis inhibitor

Hematology

Sickle cell disease

Marketed

n/d

Orphacol

FXR agonist

Gastrointestinal

Pancreatic insufficiency

Marketed

4

4/15

NeuroScientific Biopharma

Isopogen WA

StemSmart™

Stem Cell Technology

Immunology

Crohn’s disease

-

n/d

5

4/17

Channel Therapeutics

(CHRO Merger Sub)

Ligand Pharmaceuticals

(Pelthos Therapeutics)

ZELSUVMI

Nitric oxide releasing agent

Infectious disease

Molluscum contagiosum

Marketed

n/d

6

4/28

Merck KGaA

SpringWorks

Therapeutics

OGSIVEO
(nirogacestat)

γ secretase inhibitor

Oncology

Desmoid tumors

Marketed

3,900

GOMEKLI
(mirdametinib)

MEK1/MEK2 inhibitor

Neurology

NF1-PN

Marketed

7

4/28

Black Hawk
(BH Merger Sub*)

Vesicor*

ecm-RV/p53

p53 mRNA

Oncology

p53-based cancer

n/d

n/d

8

4/30

Novartis

Regulus Therapeutics

Farabursen

miR-17 inhibitor

Genitourinary

Autosomal dominant polycystic kidney disease (ADPKD)

Phase 2

800